# Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ying Cheng,Yun Fan,Yanqiu Zhao,Dingzhi Huang,Xingya Li,Peng Zhang,Mafei Kang,Nong Yang,Diansheng Zhong,Zhen Wang,Yan Yu,Yu Zhang,Jun Zhao,Tai Qin,Chenqi Chen,Shiangjiin Leaw,Wenjuan Zheng,Yong Song |
| Citations | 143 |
| DOI | 10.1016/j.jtho.2024.03.008 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.jto.org/article/S1556-0864(24)00115-1/pdf |
| OpenAlex ID | https://openalex.org/W4392554447 |
| PMID | 38460751 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Nong Yang](https://scholariq.org/researchers/nong-yang-2/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Neutropenia and Cancer Infections](https://scholariq.org/topics/neutropenia-and-cancer-infections/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.